A Pilot study utilizing escitalopram to address cognitive dysfunction in Glioma patients
Categories (click each to see list of all clinical trials associated with that category): Brain/Neuro (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Shonka, Nicole
Contact Information:
Sarah Kirke, RN
402-559-8065
sarah.kirke@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT03728673?term=NCT03728673&rank=1
Summary
This pilot study will include grade IV glioma patients treated with SSRIs during a 17 week study period. Changes in cognition/brain function and evaluation of psychosocial factors from baseline to after 17 weeks of treatment with SSRI study drug will be calculated. The investigators hypothesize that neural measures of cognition following treatment with escitalopram will experience improved cognitive and mood measures over time. The investigators will also correlate changes in mood with EEG and resting state functional (rsf)MRI. The addition of escitalopram has the potential to enhance cognitive function and hence functional independence thereby improving quality of life in these patients.